Plain language summary of a Phase II study design to test different doses of BI 1819479 in people with idiopathic pulmonary fibrosis

Plain Language SummaryWhat is this summary about?Idiopathic pulmonary fibrosis (IPF) is a lung disease that causes scarring and inflammation in the lungs. Treatments currently available for IPF can slow down the disease but do not stop or cure it, and some patients cannot tolerate the treatments that are currently available. Researchers have found that blocking a specific pathway called the lysophosphatidic acid (LPA) pathway might help treat IPF.This document explains the design of a Phase II trial that is planned for a group of people with IPF. The trial will test how well BI 1819479 works compared with placebo to treat IPF, record any adverse events that people may experience while using BI 1819479 or placebo, and establish appropriate dosing for future trials.What study medication is being investigated?A new potential medication, BI 1819479, which blocks the LPA pathway, has been tested in animals and healthy humans, and the results showed that it does not cause any unexpected serious side effects.How to say (download PDF and double click sound icon to play sound)…Idiopathic pulmonary fibrosis: id-ee-uh-PATH-ik PUHL-muh-ner-ee fai-BROH-sisLysophosphatidic acid: lye-so-fos-fuh-TID-ik as-idNintedanib: nin-TED-a-nibPirfenidone: pir-FEN-i-doneAutotaxin: aw-toh-TAK-sinImmunosuppressive: ih-myoo-noh-suh-PRES-ivPrednisone: PRED-ni-sonePharmacokinetics: far-mah-ko-ki-NET-iksPharmacodynamics: far-mah-ko-die-NAM-iksIdiopathic disease: A disease that can occur at any time without any obvious reason.Pulmonary fibrosis: A disease that causes scarring and inflammation in the lungs.Inflammation: A protective response of the body to certain events such as injury or infection that involves the immune system and tissue repair. This response can be excessive and cause damage to the body.Placebo: Tablets that look, smell and taste the same as the treatment being investigated, but do not have the active ingredient and have no therapeutic effect.Adverse events: New medical issues that a person reports after taking the trial medication or placebo during the trial. The trial physicians may decide if the new medical issues are because of the trial medication or placebo. If these adverse events are caused by the trial medication, they are called side effects.Serious side effect: A bad reaction to a medicine or treatment that can result in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, or results in birth differences or defects.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article hereTrial registration: ClinicalTrials.gov identifier: NCT06335303.